Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Generic vs. branded imatinib for CP-CML: a multicenter, observational study

Giuseppe Saglio • 17 Dec 2018
ASH 2018
Chronic Myeloid Leukemia Leukemia Imatinib

Branded imatinib was the first tyrosine kinase inhibitor (TKI) approved for chronic myeloid leukemia (CML) treatment. Generic formulations now available have since been used as a more cost-effective treatment, but there are few studies that have evaluated its efficacy and safety. Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, presents the exciting results from a multicenter, observational study that evaluated the efficacy and safety of generic vs. branded imatinib as a first-line treatment for chronic phase (CP)-CML. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
3:35
TKI-related toxicities in CML & the importance of long-term monitoring
Giuseppe Saglio • 28 Sep 2022

Related Videos

8:40
Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia
Maria Teresa Esposito • 25 Apr 2024
1:55
Factors to consider when choosing a treatment option for patients with CLL
Piers Patten • 28 Apr 2024
1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals